- Extensively XDR-TB treatment, involving specialized drug regimens to combat strains resistant to first- and second-line anti-TB drugs, is becoming increasingly critical to global public health efforts due to the limited efficacy of conventional therapies and the high mortality associated with resistant TB strains
- The escalating demand for XDR-TB treatments is primarily fueled by the rising incidence of multidrug-resistant and extensively drug-resistant TB, increased international funding for TB control programs, and accelerating efforts by governments and global health agencies to improve access to effective treatment
- Asia-Pacific dominated the extensively drug resistant tuberculosis (XDR-TB) treatment market with the largest revenue share of 39.5% in 2024, attributed to its high burden of TB cases, large-scale implementation of national control programs, and the integration of newer therapeutic regimens in alignment with global health initiatives
- Middle East and Africa is expected to be the fastest growing region in the extensively drug resistant tuberculosis (XDR-TB) treatment market during the forecast period due to rising TB case detection rates, expanding diagnostic capabilities, and increased support from international health organizations targeting drug-resistant TB in low-resource setting
- Second-Line Anti-TB Drugs segment dominated extensively drug resistant tuberculosis (XDR-TB) treatment market with a market share of 58.1% in 2024, driven by its necessity of using second-line drugs such as fluoroquinolones, bedaquiline, and delamanid in XDR-TB cases where first-line treatments are ineffective
